ELVN
Income statement / Annual
Last year (2025), Enliven Therapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Enliven Therapeutics Inc's net income was -$103.69 M.
See Enliven Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$263.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$33.00 K
|
$0.00
|
$0.00
|
| Gross Profit |
-$263.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$33.00 K
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$85.86 M
|
$80.78 M
|
$64.57 M
|
$31.02 M
|
$20.47 M
|
$8.24 M
|
$19.01 M
|
$8.24 M
|
$7.92 M
|
| General & Administrative Expenses |
$33.80 M
|
$23.78 M
|
$18.96 M
|
$7.77 M
|
$4.29 M
|
$1.08 M
|
$5.11 M
|
$2.44 M
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$33.00 K
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$33.80 M
|
$23.78 M
|
$18.96 M
|
$7.77 M
|
$4.29 M
|
$1.08 M
|
$5.07 M
|
$2.44 M
|
$987.00 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$119.40 M
|
$104.55 M
|
$83.53 M
|
$38.79 M
|
$24.76 M
|
$9.32 M
|
$24.08 M
|
$10.68 M
|
$8.91 M
|
| Cost And Expenses |
$119.66 M
|
$104.55 M
|
$83.53 M
|
$38.79 M
|
$24.76 M
|
$9.32 M
|
$24.12 M
|
$10.68 M
|
$8.91 M
|
| Interest Income |
$16.01 M
|
$14.89 M
|
$11.97 M
|
$1.13 M
|
$22.00 K
|
$483.00 K
|
$578.00 K
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$263.00 K
|
$317.00 K
|
$297.00 K
|
$215.00 K
|
$115.00 K
|
$45.00 K
|
$33.00 K
|
-$660.00 K
|
$0.00
|
| EBITDA |
-$119.40 M |
-$104.24 M |
-$83.23 M |
-$38.58 M |
-$24.65 M |
-$9.27 M |
-$23.43 M |
-$11.34 M |
$221.00 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$15.96 M
|
$15.76 M
|
$11.95 M
|
$1.13 M
|
$22.00 K
|
-$9.65 M
|
$653.00 K
|
-$660.00 K
|
$9.13 M
|
| Income Before Tax |
-$103.69 M
|
-$88.79 M
|
-$71.58 M
|
-$37.66 M
|
-$24.74 M
|
-$18.97 M
|
-$23.46 M
|
-$11.34 M
|
$221.00 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$232.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$221.00 K
|
| Net Income |
-$103.69 M
|
-$89.02 M
|
-$71.58 M
|
-$37.66 M
|
-$24.74 M
|
-$18.97 M
|
-$23.46 M
|
-$11.34 M
|
$0.00
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.83 |
-1.89 |
-2.01 |
-6.03 |
-3.17 |
-4.31 |
-5.43 |
-2.62 |
0 |
| EPS Diluted |
-1.83 |
-1.89 |
-2.01 |
-6.03 |
-3.17 |
-4.31 |
-5.43 |
-2.62 |
0 |
| Weighted Average Shares Out |
$56.66 M
|
$47.07 M
|
$35.55 M
|
$6.25 M
|
$7.81 M
|
$4.39 M
|
$4.32 M
|
$4.32 M
|
$4.32 M
|
| Weighted Average Shares Out Diluted |
$56.66 M
|
$47.07 M
|
$35.55 M
|
$6.25 M
|
$7.82 M
|
$4.39 M
|
$4.32 M
|
$4.32 M
|
$4.32 M
|
| Link |
|
|
|
|
|
|
|
|
|
